Morgan Stanley maintains Zoetis at Overweight, lowers price target to $82 from $85

Morgan Stanley kept its Overweight rating on Zoetis but reduced its price target to $82 from $85, a 3.5% decrease. The new target suggests a 5.4% upside from the Oct 28 closing price of $77.80. Recent analyst price targets for Zoetis range from $74 to $85.

Original reporting
Published Oct 29, 2026, 5:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 5:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Zoetis at Overweight, lowers price target to $82 from $85 — source image
Decision brief

The 30-second read

$ZTSBearishLow
01

Why it matters

The downgrade modestly lowers the stock's upside potential, but the change is small and may not trigger large moves.

02

Market read

A modest analyst target cut with limited immediate trading impact.

03

What to watch

Potential upcoming product launches or contract wins not reflected in the target change.

Relevance 5/10Novelty 5/10Timing: today

Background

Zoetis is a U.S.-listed animal health company (ticker ZTS). Analyst price target adjustments are common and can influence short‑term sentiment.

Company-level read

Ticker impact

$ZTSBearishHigh confidence
Context

Morgan Stanley lowered Zoetis' price target from $85 to $82, a fresh analyst downgrade.

Expected impact

likely slight pressure as the market prices in the lower target

Evidence & confidence

Target reduction signals reduced upside expectations; investors may trim positions.

Market effects

Minor impact on the animal health sector as Zoetis is a leading player.

Limited to U.S. equities; no broader regional effect.

Low global relevance; only affects Zoetis investors.

Counterpoint

Some investors may view the cut as an overreaction and see buying opportunity.

Key entities

  • Zoetis Inc.

    Animal health pharmaceutical company.

  • Morgan Stanley

    Equity research firm issuing the target cut.

Related articles

$ZTSMed

Should You Buy Zoetis Stock At This Price?

Zoetis (ZTS) stock trades at a discount, with a P/E of 13.5x vs. 22.3x for the median S&P 500 company. It has lost 29.6% over the past year. Zoetis maintains high operating margins (37.7%) but faces slowing revenue growth (0.9% YoY) and declining dermatology sales. The company is introducing new pet medicine versions and offering discounts to combat market share loss.

$ZTSMedAI 8/10

ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook

Zoetis reported Q3 2026 revenue of $2.39 billion, beating estimates by 2.6%, and adjusted EPS of $1.75, beating by 15.8%. The company raised full-year revenue and EPS guidance. Operating margin declined due to competitive pressures in the dermatology segment and promotional investments. Livestock and diagnostics segments showed growth, with the latter driven by recent acquisitions and new product launches.

$ZTSHighAI 9/10

What Zoetis (ZTS) Said on Its Q3 Earnings Call

Zoetis reported Q3 earnings, noting slowed U.S. dermatology share loss due to promotional investments. Livestock revenue rose 7% to $797M, while companion animal diagnostics revenue increased 13% to $122M. The company updated its 2026 revenue outlook to $9.22B-$9.32B and raised adjusted net income and earnings forecasts. Zoetis expects U.S. approvals for Cytopoint and Simparica Duo by year-end and Lenivia in 2027.